Mogrify to present preclinical proof-of-concept data for first-in-class retinal in vivo reprogramming therapy

The Medical News · 43m ago

Mogrify Limited (Mogrify®), a regenerative medicine company developing a novel class of in vivo reprogramming therapies, today announced it will present preclinical proof-of-concept data at FLORetina-ICOOR 2026.

Read original article on The Medical News →

Mogrify to present preclinical proof-of-concept data for first-in-class retinal in vivo reprogramming therapy

Related news